Vanda Pharmaceuticals, Northwell Health Conduct Odyssey Trial in Patients With Severe COVID-19 Pneumonia
April 16, 2020
April 16, 2020
MANHASSET, New York, April 16 -- Northwell Health issued the following news:
Vanda Pharmaceuticals Inc. and Northwell Health's research arm, the Feinstein Institutes for Medical Research, announced enrollment of the first patient in Vanda's clinical trial, ODYSSEY VLY-686-3501 (NCT04326426), yesterday at Lenox Hill Hospital in New York City.
ODYSSEY is a Phase III double-blind placebo-controlled trial investigating the efficacy and safety of tradipitant, a neurokinin-1 . . .
Vanda Pharmaceuticals Inc. and Northwell Health's research arm, the Feinstein Institutes for Medical Research, announced enrollment of the first patient in Vanda's clinical trial, ODYSSEY VLY-686-3501 (NCT04326426), yesterday at Lenox Hill Hospital in New York City.
ODYSSEY is a Phase III double-blind placebo-controlled trial investigating the efficacy and safety of tradipitant, a neurokinin-1 . . .